- Home
- CLYM vs IFRX Comparison
CLYM vs IFRX Comparison
Compare CLYM & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- IFRX
- Stock Information
- Founded
- CLYM 2018
- IFRX 2007
- Country
- CLYM United States
- IFRX Germany
- Employees
- CLYM N/A
- IFRX N/A
- Industry
- CLYM
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- CLYM
- IFRX Health Care
- Exchange
- CLYM NYSE
- IFRX Nasdaq
- Market Cap
- CLYM 101.6M
- IFRX 117.8M
- IPO Year
- CLYM 2021
- IFRX 2017
- Fundamental
- Price
- CLYM $1.47
- IFRX $1.83
- Analyst Decision
- CLYM
- IFRX Strong Buy
- Analyst Count
- CLYM 0
- IFRX 1
- Target Price
- CLYM N/A
- IFRX $8.00
- AVG Volume (30 Days)
- CLYM 331.6K
- IFRX 498.3K
- Earning Date
- CLYM 03-27-2025
- IFRX 03-20-2025
- Dividend Yield
- CLYM N/A
- IFRX N/A
- EPS Growth
- CLYM N/A
- IFRX N/A
- EPS
- CLYM N/A
- IFRX N/A
- Revenue
- CLYM N/A
- IFRX $187,930.00
- Revenue This Year
- CLYM N/A
- IFRX $396.02
- Revenue Next Year
- CLYM N/A
- IFRX $155.22
- P/E Ratio
- CLYM N/A
- IFRX N/A
- Revenue Growth
- CLYM N/A
- IFRX 177.12
- 52 Week Low
- CLYM $1.41
- IFRX $1.17
- 52 Week High
- CLYM $11.55
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- IFRX 32.97
- Support Level
- CLYM N/A
- IFRX $1.76
- Resistance Level
- CLYM N/A
- IFRX $1.98
- Average True Range (ATR)
- CLYM 0.00
- IFRX 0.19
- MACD
- CLYM 0.00
- IFRX -0.08
- Stochastic Oscillator
- CLYM 0.00
- IFRX 6.65
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.